SCHEMBL770931

SCHEMBL770931

O=C(CCN1C(=O)[C@@H]2CCCC[C@H]2C1=O)N1CCC2CCCCC2C1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
RAB9A P51151 2/20 0.49
MAPK1 P28482 2/20 0.46
ALDH1A1 P00352 6/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.40
HSD11B1 P28845 1/20 0.40
HPGD P15428 3/20 0.39
KMT2A Q03164 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 1/20 0.39
ATM Q13315 1/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL795400 1.00 SMN1; SMN2 (0.49) SMN1; SMN2RAB9AMAPK1ALDH1A1CASP1
SCHEMBL771965 0.92 SMN1; SMN2 (0.48) SMN1; SMN2RAB9AMAPK1ALDH1A1HSD11B1
SCHEMBL771364 0.86 MEN1 (0.51) RAB9AALDH1A1L3MBTL1HSD11B1KMT2A
SCHEMBL770300 0.82 MAPK1 (0.70) SMN1; SMN2MAPK1ALDH1A1HPGDKMT2A
SCHEMBL771655 0.80 HSD11B1 (0.51) ALDH1A1HSD11B1KMT2AATMMEN1
SCHEMBL771365 0.79 MAPK1 (0.57) SMN1; SMN2MAPK1ALDH1A1HPGDKMT2A
SCHEMBL24323871 0.77 RAB9A (0.51) SMN1; SMN2RAB9AMAPK1ALDH1A1CASP1
SCHEMBL769788 0.77 NPC1 (0.52) L3MBTL1HSD11B1KMT2AATMMEN1
SCHEMBL770400 0.77 GNAI3 (0.51) MAPK1ALDH1A1L3MBTL1HSD11B1HPGD
SCHEMBL771859 0.76 ALDH1A1 (0.50) SMN1; SMN2RAB9AMAPK1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3653/4885RAB9A 2187/4885MAPK1 401/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3637/4885RAB9A 2217/4885MAPK1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.